In order to evaluate whether the presence of the PNPLA3 I148M variant may even interfere with hepatic NAD metabolism, we assessed the expression of genes involved in NAD biosynthetic pathways as well as NAD/NADH-dependent enzymes through RNA-seq analysis performed in 183 biopsied NAFLD patients (Transcriptomic cohort) who underwent bariatric surgery. The gene discussed is PNPLA3; the disease is metabolic dysfunction-associated steatotic liver disease.